Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gynaecological cancers

859 - Survival, clinical activity and safety of intraperitoneal carboplatin combined with intravenous dose-dense paclitaxel in patients with ovarian carcinoma: a retrospective study of 69 cases


19 Dec 2015


Gynaecological cancers


Yuichi Imai


Annals of Oncology (2015) 26 (suppl_9): 80-84. 10.1093/annonc/mdv525


Y. Imai, K. Hasegawa, S. Sato, Y. Yano, A. Ogasawara, A. Miyasaka, A. Yabuno, A. Kurosaki, H. Yoshida, K. Fujiwara

Author affiliations

  • Gynecologic Oncology, Saitama Medical University International Medical Center, 350-1298 - Hidaka, Saitama/JP

Abstract 859


Intraperitoneal (IP) chemotherapy with cisplatin demonstrated better prognosis for optimally debulked stage III ovarian cancer. Although, it has not been widely accepted yet due to its complications. On the other hand, intravenous (IV) dose-dense paclitaxel and carboplatin therapy also showed improved survival compared to the conventional paclitaxel and carboplatin for the treatment of advanced ovarian cancer. IP carboplatin was reported to have more reasonable pharmacokinetics than IV carboplatin. The efficacy of IP carboplatin in combination with IV dose-dense paclitaxel for ovarian cancer has not been addressed yet.


We retrospectively analyzed the survival, efficacy and safety of 69 patients with stage II-IV ovarian, fallopian tube, and primary peritoneal carcinoma who underwent IP carboplatin in combination with IV dose-dense paclitaxel (ddTCip) as a frontline chemotherapy.


Eleven and 58 patients underwent optimally and suboptimally debulked surgery, respectively. We observed 91.4% patients had clinical response for ddTCip therapy. Ten and 43 patients showed complete and partial response, respectively. Median follow-up of alive patients was 47 months, median PFS was 19 months, and median OS was 61 months. We observed 89.9%, 55.1% and 20.3% cases had grade 3/4 neutropenia, anemia, and thrombocytopenia, respectively. Port-related adverse events occurred in 8 (11.6%) patients.


We suggest that the frontline chemotherapy with ddTCip therapy is safe and effective even for suboptimally debulked stage II-IV ovarian carcinoma patients. A randomized phase III trial comparing IP versus IV carboplatin in combination with IV dose-dense paclitaxel is currently ongoing.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings